Latest News
MercadoLibre Gains Despite JPMorgan Target Cut Amid Brazil Margin Concerns
MercadoLibre stock edged higher Monday, shrugging off a price target reduction by JPMorgan, which maintained an Overweight rating but flagged competitive margin pressures in Brazil.
Travel Stocks Lose $22.6B as Oil Spike, Flight Cancellations Mount
Booking Holdings declined 0.7% as the broader travel sector shed $22.6 billion in market value. The selloff was driven by a 13% spike in oil prices and major flight disruptions linked to Middle East conflict.
Travel Stocks Slide on Geopolitical Tensions, Oil Spike
Booking Holdings shares fell alongside the broader travel sector Monday, pressured by surging oil prices and widespread flight cancellations linked to Middle East tensions. The company's 25-for-1 stock split is scheduled for early April.
Apple Launches iPhone 17e at $599, Sparking Renewed Investor Debate
Apple has introduced the iPhone 17e with a starting price of $599 and doubled base storage, alongside an M4-powered iPad Air. The launch has reignited discussions among investors about the stock's potential after a sustained rally.
Apple Launches iPhone 17e at $599, Sparking Renewed Investor Debate
Apple has introduced the iPhone 17e with a starting price of $599 and doubled base storage to 256GB, alongside an M4-powered iPad Air. The company's shares gained 0.9%, reigniting discussions about its stock's valuation and growth potential.
AeroVironment Plummets on SCAR Contract Uncertainty, Raymond James Downgrade
AeroVironment shares tumbled almost 19% Monday following a Raymond James downgrade to Underperform. The broker highlighted uncertainty surrounding the U.S. Space Force's $1.4 billion SCAR satellite-communications contract.
AeroVironment Plunges on Downgrade Amid SCAR Contract Uncertainty
AeroVironment shares tumbled almost 19% Monday following a Raymond James downgrade to Underperform, driven by uncertainty over a key U.S. Space Force contract.
Lilly Shares Dip Amid Sector Weakness, Focus on Obesity Drug Pipeline
Eli Lilly shares declined 2.3% to $1,028.07 on Monday, underperforming the broader market. The focus remains on the company's obesity drug pipeline and an upcoming FDA review for its oral GLP-1 candidate, orforglipron.
Lilly Shares Slip Amid China Drug Approval, Focus on Obesity Pipeline
Eli Lilly shares declined 2.3% to $1,028.07 Monday despite broader market gains. The dip came as Innovent Biologics secured Chinese regulatory clearance for the cancer therapy Jaypirca, a drug developed with Lilly.
Western Digital Stock Dips Amid 32TB Drive Shipment Data, AI Demand Focus
Western Digital stock declined approximately 3% during Monday trading, underperforming broader indices. The company disclosed it shipped 3.5 million units of its high-capacity 32TB nearline hard drives in the previous quarter.